Approved by the FDA in May 2024, Moderna’s mRNA shot, mRESVIA, only generated $10 million in sales during the third quarter, its RSV season debut. Besides the impact of a narrowed CDC policy ...

Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped.

As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...

20, 2023, in Cypress, Texas. Weak adoption of Moderna’s respiratory syncytial virus (RSV) vaccine has exacerbated financial pressures, with the product... Pharmacist Kim Nguyen administers a ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

Demand for its COVID vaccine has been waning since the pandemic, while adoption of its RSV shot - its second approved product- has been slower than expected, forcing Moderna to cut costs.

Moderna launched RSV vaccine mResvia in 2024 as the third-to-market product behind GSK and Pfizer vaccines. However, the firm's pipeline progress could lead to 2025-27 launches for a covid/flu ...

amid its advantages over some of the other RSV vaccines. Moderna’s RSV shot can be stored frozen and comes in a syringe, implying faster and easy administration. It also has no reported Guillain ...

Moderna's mRESVIA joined the market after RSV vaccines from Pfizer and GSK already had established themselves. At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $ ...

"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the next three years, and reducing costs across our business." MRNA Stock Is in a ...

(AP Photo/Eugene Hoshiko, File)(Eugene Hoshiko / AP) Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by slow adoption of its respiratory syncytial virus (RSV) shot and weak ...

Through the first nine months of 2024, Moderna's revenue of $2.3 billion represents a 44% decline year over year. This figure includes a mere $10 million in sales of the new RSV vaccine following ...